Trastuzumab
- CAS No.
- 180288-69-1
- Chemical Name:
- Trastuzumab
- Synonyms
- Herceptin;Trastuzumab Beta;RhuMab HER2;Anti-Trastuzumab;TRASTUZUMAB 95 % +;TRASTUZUMAB 98 % +;Trastuzumab USP/EP/BP;TrastuzuMab(Herceptin);Trastuzumab (anti-HER2);Trastuzumab,Stock solution
- CBNumber:
- CB61074602
- Molecular Formula:
- C10H14N6O5
- Molecular Weight:
- 298.25536
- MDL Number:
- MFCD03702625
- MOL File:
- 180288-69-1.mol
| storage temp. | Store at -20°C |
|---|---|
| form | Solid |
| color | White to light yellow |
| NCI Dictionary of Cancer Terms | Herceptin |
| FDA UNII | P188ANX8CK |
| NCI Drug Dictionary | Herceptin |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H360 |
| Hazardous Substances Data | 180288-69-1(Hazardous Substances Data) |
Trastuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth Carbosynth | FT65040 | Trastuzumab - 20mg/ml in PBS | 180288-69-1 | 1mg | $78 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FT65040 | Trastuzumab - 20mg/ml in PBS | 180288-69-1 | 2mg | $120 | 2021-12-16 | Buy |
| ChemScene | CS-7821 | Trastuzumab 99.30% | 180288-69-1 | 1mg | $192 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FT65040 | Trastuzumab - 20mg/ml in PBS | 180288-69-1 | 5mg | $240 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FT65040 | Trastuzumab - 20mg/ml in PBS | 180288-69-1 | 10mg | $420 | 2021-12-16 | Buy |
Trastuzumab Chemical Properties,Uses,Production
Uses
Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer.
Indications
The introduction of herceptin (Trastuzumab) into clinical practice for the treatment of breast cancer marks a major advance in the use of monoclonal antibody cancer therapy. Herceptin is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. HER-2/neu/erbB2 overexpression marks an aggressive estrogen receptor–negative form of breast cancer. Therefore, a therapeutic agent selective for this target is particularly valuable. Herceptin is administered by intravenous infusion and in conjunction with paclitaxel can extend survival in patients with HER-2/neu/erbB2 overexpressing metastatic breast cancer.Herceptin use is associated with infusion- related hypotension, flushing and bronchoconstriction, and skin rash but no bone marrow toxicity. Herceptin appears to sensitize patients to cardiotoxicity, an important concern in patients also receiving doxorubicin.
Definition
Herceptin (generic name: trastuzumab) is not a chemo drug, it is a targeted therapy anticancer drug.
Herceptin contains one active ingredient, trastuzumab, and is given as an intravenous (IV) infusion slowly into a vein. Herceptin Hylecta contains two active ingredients, trastuzumab and hyaluronidase-oysk, and is given as a subcutaneous injection, which is an injection that goes under the skin.
Mechanism of action
Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2-mediated signaling. It is also thought to facilitate antibody-dependent cellular cytotoxicity, leading to the death of cells that express HER2. Its mechanism differs slightly from that of the newer agent pertuzumab; the latter inhibits hetero-dimerization of HER2 with HER3, a related growth factor receptor. Trastuzumab has been shown to bind three distinct regions of domain IV of the HER2 extracellular domain through electrostatic and hydrophobic bindings[1].
References
[1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).
Trastuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | sales@minbiotech.com | CHINA | 129 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21634 | 55 |
| SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 | sales@sdzschem.com | China | 2930 | 58 |
| Biochempartner | 0086-13720134139 | candy@biochempartner.com | CHINA | 965 | 58 |
| Hubei xin bonus chemical co. LTD | 86-13657291602 | linda@hubeijusheng.com | CHINA | 22963 | 58 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | factory@coreychem.com | China | 29811 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32161 | 58 |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10319 | 58 |
| HONG KONG IPURE BIOLOGY CO.,LIMITED | 86 18062405514 18062405514 | ada@ipurechemical.com | CHINA | 3461 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 22784 | 58 |
Related articles
- Pharmacological effects of trastuzumab
- Trastuzumab, an anti-Her 2 monoclonal antibody, blocks the growth of cancer cells by attaching itself to Her2 to block the att....
- Jul 4，2022
View Lastest Price from Trastuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-12-13 | Trastuzumab
180288-69-1
|
US $0.00 / G | 1G | 98%min | 30kg/month | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2024-11-19 | Trastuzumab
180288-69-1
|
US $157.00-689.00 / mg | 99.50% | 10g | TargetMol Chemicals Inc. | ||
 |
2021-07-03 | Trastuzumab USP/EP/BP
180288-69-1
|
US $1.10 / g | 1g | 99.9% | 100 Tons Min | Dideu Industries Group Limited |
-
- Trastuzumab
180288-69-1
- US $0.00 / G
- 98%min
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Trastuzumab
180288-69-1
- US $157.00-689.00 / mg
- 99.50%
- TargetMol Chemicals Inc.
-
- Trastuzumab USP/EP/BP
180288-69-1
- US $1.10 / g
- 99.9%
- Dideu Industries Group Limited
180288-69-1(Trastuzumab)Related Search:
1of4